Navigation Links
Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Date:11/11/2008

KANSAS CITY, Mo., Nov. 11 /PRNewswire/ -- An investor group in Trinity Biotech plc (Nasdaq: TRIB), an Irish based developer and manufacturer of diagnostic products whose shares are traded in the form of American Depository Receipts ("ADRs") on NASDAQ, has initiated a campaign for conversion of company ADRs to ordinary shares to bring about a special meeting of shareholders to consider a change in the board.

This campaign follows the recent refusal by Trinity Biotech directors to honor an earlier request by a group of ADR holders for the calling of a special meeting of shareholders to consider the removal and replacement of the company's current directors. The directors' rejection of the request was based on their determination that ADRs have fewer rights under Irish law than the ordinary shares into which they may be converted. The directors also refused to take alternative steps proposed by the requesting group to convene the meeting.

Commenting on the campaign, Tom Reidy stated, "The directors' blatant disregard for our basic rights as owners of the company has only heightened our resolve to impose accountability on company management. We are calling on all ADR holders who believe that a board change is in order to join with us in converting ADRs to ordinary shares. While none of us should be forced to take this unnecessary step, we believe this is the only way we can protect our investment."

Important Next Steps: ADR holders who would like assistance in converting their ADRs should contact Mr. Reidy at tjreidy3@hotmail.com or (816) 260-8476.


'/>"/>
SOURCE KC Investor Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders
2. Investor Call Scheduled to Discuss Ouster Proposal of Trinity Biotech Directors
3. Trinity Biotech plc to Announce Third Quarter 2008 Financial Results on October 31, 2008
4. Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
5. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
6. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
7. Yongye Biotechnology to Present at Roth Capital China Comes to Vegas Conference
8. InterMune to Present at Deutsche Bank Biotech Boston Confab
9. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
10. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman & Renshaw 10th Annual Healthcare Conference
11. Oncolytics Biotech Inc. Investigators Present Interim U.S. REOLYSIN(R) Phase II Sarcoma Trial Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is pleased ... received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of ... Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform ...
Breaking Biology Technology:
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... April 15, 2016 Research ... Gait Biometrics Market 2016-2020,"  report to their offering.  ... ) , ,The global gait biometrics market is ... during the period 2016-2020. Gait analysis ... can be used to compute factors that are ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):